CN102443641A - Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof - Google Patents
Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof Download PDFInfo
- Publication number
- CN102443641A CN102443641A CN2011104260606A CN201110426060A CN102443641A CN 102443641 A CN102443641 A CN 102443641A CN 2011104260606 A CN2011104260606 A CN 2011104260606A CN 201110426060 A CN201110426060 A CN 201110426060A CN 102443641 A CN102443641 A CN 102443641A
- Authority
- CN
- China
- Prior art keywords
- hybridization
- microrna
- cancer
- test kit
- detection method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 89
- 201000011510 cancer Diseases 0.000 title claims abstract description 64
- 238000001514 detection method Methods 0.000 title claims abstract description 37
- 238000007901 in situ hybridization Methods 0.000 title claims abstract description 11
- 230000007170 pathology Effects 0.000 title claims abstract description 10
- 238000009396 hybridization Methods 0.000 claims abstract description 53
- 239000000523 sample Substances 0.000 claims abstract description 41
- 238000000034 method Methods 0.000 claims abstract description 33
- 239000000758 substrate Substances 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims description 20
- 238000011065 in-situ storage Methods 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 229930003756 Vitamin B7 Natural products 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000011735 vitamin B7 Substances 0.000 claims description 4
- 235000011912 vitamin B7 Nutrition 0.000 claims description 4
- 241001529572 Chaceon affinis Species 0.000 claims description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 239000002086 nanomaterial Substances 0.000 claims description 2
- 239000000941 radioactive substance Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000012747 synergistic agent Substances 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 33
- 238000012216 screening Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000005856 abnormality Effects 0.000 abstract 2
- 238000003384 imaging method Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 29
- 238000013016 damping Methods 0.000 description 28
- 239000012530 fluid Substances 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 239000002679 microRNA Substances 0.000 description 25
- 238000011282 treatment Methods 0.000 description 24
- 108700011259 MicroRNAs Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 238000003745 diagnosis Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 108091070501 miRNA Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 235000011194 food seasoning agent Nutrition 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 238000002059 diagnostic imaging Methods 0.000 description 4
- 210000002249 digestive system Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000012151 immunohistochemical method Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000155 isotopic effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- VOZKAJLKRJDJLL-UHFFFAOYSA-N 2,4-diaminotoluene Chemical compound CC1=CC=C(N)C=C1N VOZKAJLKRJDJLL-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101001120822 Homo sapiens Putative microRNA 17 host gene protein Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108091027766 Mir-143 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 241000768494 Polymorphum Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100026055 Putative microRNA 17 host gene protein Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091074057 miR-16-1 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000021368 organ growth Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an in situ hybridization detection kit which comprises a hybridization probe and a tag. The invention also discloses an in situ hybridization detection method for the microRNA-16 closely related with the various early-stage cancer pathology evolution through the kit. The method comprises the following steps: 1, contacting RNA to be detected in a substrate with the hybridization probe on condition that the hybridization probe and a target sequence can form a stable hybridization complex; and 2, detecting the hybridization complex. According to the kit and the detection method of the invention, the microRNA-16 expression level can be detected at the RNA level, and the abnormality of the microRNA-223 expression level is earlier than the abnormality of indexes detected with the imaging medicine and the present clinical biochemistry, so real early-stage canceration RNA level screening can be realized. The detection method which has the advantages of simplicity, convenience and low cost is convenient for the popularization and the application in county and district hospitals.
Description
Technical field
The present invention relates to field of biological detection, more particularly, relate to develop the correlation detection technology that rna expression changes (pathology evolution process) with various cancer pathology.
Background technology
According to the data that domestic and international authoritative institution provides, the newly-increased number 2,600,000 of the annual cancer of China, death toll nearly 2,100,000; The patient more than 700 ten thousand; The annual newly-increased cancer patients 8,000,000 in the whole world, death toll is near 8,000,000, and the patient has more than 8,400 ten thousand people approximately; To double to the above number of the year two thousand twenty, this is one group of fearful numeral.Cancer diagnosis and treatment cost is increasingly high; (poor area maybe be higher by cancer patients's year medical expense 200,000; Developed regions possibly exceed 200,000 far away), more than 700 ten thousand patients, annual cost is 1.4 trillion Renminbi; Deduction cost 35% is about 400,000,000,000, has every year 1000000000000 Renminbi to consume in vain approximately.And the cancer patients is most of can be dead soon after treatment.Therefore, existing clinical cancer diagnosis and treatment pattern must change, and innovative point of the present invention is to accomplish preventative examination in advance, in time gets involved preventative regulation and control and prophylactic treatment then, accomplishes preventiveing treatment of disease of gene level cancer.
An annual report has been done by eight tame units such as U.S. sanitary research institute in 2005, cancer research institute, Disease Control and Prevention Center; Anticancer Great War to initiation in 1972 is looked back; Report thinks that the mankind are failures in anticancer Great War; Conclusion is that cancer mortality does not reduce, and it is enumerated out and causes the Several Factors of anticancer Great War failure to be: 1. tumour cell heterogeneous (polymorphum); 2. tumor cell drug resistance; 3. cancer therapy drug mentality of designing imperfection (animal model designs not science) etc.Simultaneously, also propose to examine closely again the measure of existing diagnosis and treatment cancer in this report.
The inventor is in the middle discovery that studies for a long period of time, and the major reason that causes cancer mortality not fallen is to accomplish real early diagnosis.Come diagnosing cancer according to existing clinical medicine image (B ultrasonic, CT, zeugmatography etc.) and with other biochemistry (cancer antigen, CEACAMS, carbohydrate hormone, the cytolemma factor, the nucleus factor, cell streaming technology) index; All be that tumour forms the back diagnosis; The former will learn in a organized way and change or existing occupying lesion, latter's major part be tumour form the back secreted, discharge or the affinity tag of tumour.The clinical idea of tradition thinks that occupancy cancer piece is the diagnosis that belongs to early-stage cancer under 2 centimeters; This notion is worth conscientiously discussing, and it is rigorous inadequately that 2 centimeters early stage these of following cancer piece genus define science, analyzes from the cytology angle; 1 centimeter lump has 100,000,000 tumour cells approximately; Its three-dimensional cell stack number of 2 centimeters lump is far above 200,000,000 tumour cells, produces from canceration early stage to the mono-clonal cancer cells and forms 2 centimeters cancer piece, and its pathology evolution process is quite long; Possibly be (except the special case) more than 5 years or 10 years or even 10 years; What be difficult to confirm is in this pathology evolution process, and lump is unique spot of cancer and independent focus, and possible cancer cells is moved to other tissue or organ growth already.Clinical study confirms already, in case when forming lump, other cancer cells is moved to other position clonal growth through different approaches, in case behind the excision primary tumor, other organ recurrent foci or multiple cancer piece kitchen range successively form.Therefore; Whether define in early days with the cancerous swelling piece size below 2 centimeters clinically, rigorous inadequately (some case is when finding primary lesion; Find metastatic lesion simultaneously; Not in the content of our statement), at this moment be diagnosis in late period and treatment of late stage in fact, this is the true cause that causes cancer mortality not fallen.
Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics in order to seek more early stage diagnosing cancer, treatment cancer and preventing cancer, makes great progress.So far, we might do more accurate early screening and diagnosis on the one-level functional transcription product (mRNA level or microRNA) of gene, preceding in canceration early stage or cancer cells formation (mono-clonal), just can accomplish early prediction and examination.
MiRNA (microRNA/miRNA) is the few ribonucleic acid molecule that a segment length is about 22 nucleotides, and they can suppress translation or cause the degraded of mRNA to reduce the performance of gene by regulation and control mRNA.Many discovering arranged recently, and miRNA and cancer have the dependency of height.Therefore inference miRNA possibly be of cancerization process lead because of.Up to the present; On human body, there are 700 miRNA of surpassing to come to light; And nearly about 100 miRNA is identified with human cancer and has dependency; This wherein includes kinds of tumors such as esophagus cancer, breast cancer, leukemia, lung cancer, the cancer of the brain, liver cancer, carcinoma of the colon and rectum, glioma, pituitary tumor in esophageal cancer cell, microRNA up-regulateds in kinds of tumors such as miR-17-92 family.A kind of miR-21 is up-regulated expression in many malignant tumours such as glioblastoma, mammary cancer, carcinoma of the pancreas, colorectal carcinoma, liver cancer, lung cancer, prostate cancer, cancer of the stomach.
Though tumor tissues microRNA express spectra is relevant with tumor invasion and prognosis, detection technique is complicated, wound is big, is difficult to really be applied to clinical diagnosis.Comparatively speaking, peripheral blood serum is prone to obtain and detect, and clinical application is convenient, is beneficial to popularization.Whether exist the express spectra of serum microRNA related in the serum with corresponding tumor tissues microRNA express spectra.So far reported the research work of multinomial serum microRNA and tumour relation in 2008, for serum microRNA provides working foundation as early diagnosis and the prognosis that molecule marker is applied to tumour.MicroRNA can steady in a long-term exist in serum, the enzyme liberating of anti-RNA, the loss that boil, various treatment processs such as multigelation, acid or alkali environment, prolonged preservation all can not cause serum microRNA.The source of serum microRNA does not still have final conclusion, generally believes that now it derives from histiocytic active secretion process.Sophisticated microRNA is encapsulated into excision enzyme body (Exosome) by lipid or lipoprotein in cell, secrete to born of the same parents and get into blood; The excision enzyme body that gets into blood can get into recipient cell and go and encapsulate through endocytosis, discharges microRNA performance biological function.The exchange of the iuntercellular microRNA of excision enzyme body mediation; It is a kind of new approach of cell communication; To the stable state of environment in the keeping mark of serum microRNA that play an important role as diagnosing tumor and prognosis; Mainly contain following advantage: the damage of detection is little, good stability, highly sensitive, can be applicable to the detection of infantile tumour.But because the expression amount of microRNA is lower in the serum, seeking a kind of detection method highly sensitive, easy and simple to handle and with low cost is that present serum microRNA is applied to clinical tumor detection problem demanding prompt solution.MicroRNA is the little RNA of non-coding of one type of high conservative, main through the 5pUTR, coding region or the 3pUTR that combine target gene mRNA on post-transcriptional level to expression of gene row negative regulation function, the mode that microRNA participates in gene expression regulation mainly is to suppress the carrying out of translation process; Also can cause the mRNA degraded under the few cases; Bioinformatic analysis shows that each microRNA possibly regulate hundreds of target genes, and prompting microRNA possibly participate in regulating signal transduction pathways numerous in the cell activities; In a series of processes such as cell proliferation, differentiation, apoptosis, immunoreation and vasculogenesis, play a role; MiR-16-1, miR-143, miR-145 etc. can be because of p53; P68 and Drosha mixture interact and up-regulated, thereby suppress cell proliferation.The microRNA abnormal expression can have a strong impact on the effect of cellular signal transduction pathways, causes cell proliferation out of hand with differentiation, finally causes the generation of tumour.
The present invention selects many group clinical samples (cancer patient, high risk population, normal control) to adopt nucleic acid hybridization in situ technology and immunohistochemical methods method that check and analysis are carried out in the early warning of microRNA-16 and various cancers.
The inventor finds that under study for action microRNA-16 has the obvious expression quantitative changeization various cancer patientss, cancer high risk population, normal control people, and microRNA-16 is become as the various cancers of early screening has very important clinical diagnosis meaning early stage.MICRORNA-16 becomes low expression the in the process in early stage in various cancers.He do in examination in canceration early stage, and various cancer therapy after recurrence, shift early warning very important clinical meaning also arranged.
The contriver is in long term studies; Drawn a kind of new concept, the clinical diagnosis and treatment pattern of cancer and other clinical major disease must change, and can not only stop present treating the disease affected (morbidity back diagnosis and treatment); Accomplish preventative diagnosis and treatment; Accomplish treating the disease affected, only in this way could reduce the M & M of major disease, reduce social cost and medical treatment cost.Therefore, the contriver innovates theoretical and technical in the rna level kit for screening and medicine of exploitation and production major disease.Particularly screen clinical samples (normal population, cancer high risk population, tumour patient); Broken through healthy tissues and tumor tissues consistency research and development thinking relatively, sought and developed the rna level that becomes before the cancer, developed closely related with cancer early gene physiopathology; And the extremely important target of clinical meaning; Tumour is clinically formed the preventative diagnosis and treatment that diagnosis and treatment pattern in back becomes tumour, striven for the time and the space of tumor diagnosis and treatment, reach preventing cancer.
At present; MICRORNA-16 express spectra detection method is analyzed technology with Northern hybridization, expression chip, real-time fluorescence quantitative PCR and Solexa order-checking etc.; And these methods are used for the scientific research aspect more, the incompatibility clinical application, and detect RNA than genetic analysis more science (the DNA analysis major part is on the presentation of susceptibility; RNA is functional embodiment), than analysis of protein more reliable (RNA and albumen are transcribed sometimes asynchronous).The detection technique and the test kit that adopt hybridization in situ technique and groupization immunization method to detect MicroRNA-16 horizontal expression amount according to the existing literature data do not appear in the newspapers.
The inventor is in the requirement to the novelty invention; Designed (patients with lung cancer, high risk population, normal control) different pieces of information example group; Detect with hybridization in situ technique; The result shows that lung cancer patient MICRORNA-16 is low and expresses, and the high risk population has and expresses 15-25% in various degree, and normal control all is a high expression level.Show that the various cancers of MICRORNA-16 become the important symbol thing of examination in early stage.
Hybridization in situ technique (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark; Under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized; With radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.
The probe of in situ hybridization is molecule or sequence the unknown but the known nucleic acid molecule of molecule (though indeterminate this molecule full sequence of known array; But known its is directed against target molecule), the kind of probe can be divided into dna probe, cDNA probe, cRNA probe and synthetic oligonucleotide probe again by the properties of nucleic acids difference.For the ease of spike, probe must be used certain means mark in addition, is beneficial to later detection.Affinity tag commonly used comprises radionuclide and non-radioactive marker's two big classes.Isotopic label commonly used has
3H,
35S,
125I with
32P.Advantages such as susceptibility is high though isotopic label has, the back of the body end is comparatively clear because ri all can damage human and environment, have by the substituted trend of heterotope recently.At present the most frequently used in the heterotope affinity tag have three kinds of vitamin H, digoxin and resorcinolphthaleins.The method that detects these affinity tags all is a sensitive extremely.
According to used probe and to detect nucleic acid difference can be divided into DNA-DNA again, RNA-DNA, RNA-RNA hybridization.No matter but the hybridization of any form, all must be through five big processes, promptly histiocytic fixing, prehybridization, hybridization, flushing and demonstration.The present invention adopts the hybridization mode of RNA-RNA, and synthetic probe (RNA) and the target RNA that detects are the principles that adopts base complementrity (hybridization is complementary), simultaneously through long-time research with observe, start and termination place the result not influence of residue to detecting.
In view of the diagnosis of cancer clinically (medical imaging and biochemical indicator thing all are the diagnosis after tumour forms) at present is the diagnosis in late period, treatment also is a treatment of late stage, the treatment pattern that causes mortality ratio not fallen.Original intention of the present invention is to want to change at present the diagnosis and treatment pattern of major disease clinically; Become preventative preventiveing treatment of disease from treating the disease affected; Reach preventative diagnosis and treatment; Present medical imaging means and numerous biochemical marker can't be detected become rna level before the cancer and quantize changes technology, do the technological breakthrough of novelty, provide that to become the rna level examination before the cancer technological.Making has had a preceding technology that becomes the real early screening of rna level of new cancer clinically, for the diagnosis and treatment of clinical cancer are raced against time and the space.
Summary of the invention
The object of the invention at first provides a kind of hybridization in situ detection kit, and it comprises in situ hybridization detection probes and affinity tag.Secondly, the present invention also will provide the mentioned reagent box to be used for shifting the relevant in situ hybridization detection method of early warning with various canceration examinations in early stage and treatment back.
For realizing the object of the invention; Technical scheme of the present invention is following: the present invention at first provides a kind of hybridization in situ detection kit, and it comprises hybridization probe and affinity tag, wherein; Described hybridization probe is the complementary sequence of sequence shown in the sequence table SEQ ID NO.1; Sequence number: NR_029486, nucleotide sequence length is 89bp, is positioned at karyomit(e) 13q14.2 " on.
A preferred version of test kit of the present invention is that described affinity tag is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, resorcinolphthalein, enzyme and nano material.
A preferred version of test kit of the present invention is also to comprise hybridization solution.
A preferred version of test kit of the present invention is also to comprise toughener.
A preferred version of test kit of the present invention is also to comprise developer.
Canceration MICRORNA-16 kit for screening in early stage using value of the present invention is, to various canceration examinations in early stage, reaches cancer treatment back recurrence, shifts, spreads early warning takes place, and further cooperates clinical treatment.
The present invention also provides a kind of detection method of MICRORNA-16 in situ hybridization, may further comprise the steps:
(1) described in the above hybridization probe and target sequence can form under the condition of stablizing hybridization complex, and RNA to be measured in the substrate is contacted with hybridization probe, form hybridization complex; With
(2) detect said hybridization complex.
Detection method of the present invention, wherein preferably, the described condition of stablizing hybridization complex that forms is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour.
Detection method of the present invention, wherein preferably, described substrate is selected people's blood leucocyte sample or other organ-tissue cell specimen for use.More preferably be that described blood preparation or other organ-tissue cell specimen are from various cancer patientss, cancer high risk population, healthy normal population.
Detection kit of the present invention is to adopt nucleic acid hybridization technique and groupization immunization method to combine; With MICRORNA-16 is detected object; Synthesising probing needle is the complementary sequence of MICRORNA-16 sequence, and the substrate of detection is the expression amount of blood of human body sample white corpuscle or histiocytic RNA.The display packing of hybridization in situ technique can provide sxemiquantitative or the quantitative expression deciding degree of MICRORNA-16.The expression amount of above RNA is judged in colour developing according to hybridization back immunohistochemical methods, normal people MICRORNA-16 high expression level, i.e. and colour developing in a large number, MICRORNA-16 has apparent difference at various cancer patients and normal control, and this expression of gene amount is all lower than normal people expression amount.
The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein the concrete steps of hybridization comprise:
1). sample to be measured is put into reactive tank;
2). instrument discards liquid automatically, adds Digestive system automatically;
3). instrument discards liquid automatically, and the back is fixing automatically;
4). instrument discards liquid automatically, automatically prehybridization (42 ℃);
5). instrument discards liquid automatically, cleans automatically;
6). instrument discards liquid automatically, automatically hybridization (42 ℃);
7). instrument discards liquid automatically, cleans automatically;
8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);
9). instrument discards liquid automatically, cleans colour developing automatically;
10). take out the mounting microscopy.
The scheme of a preferred embodiment of the present invention is: with MICRORNA-16 synthetic nucleic probe with digoxigenin labeled (cDNA of digoxigenin labeled, RNA and oligonucleotide probe; Not only probe has a biotin labeling advantage; Also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position); This hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized,, under light microscopic, observe existence and the location of RNA again with the method colour developing of immunohistochemical methods; According to painted cell count, judge the expression amount of purpose RNA.
The inventive method is a nucleic acid hybridization in situ technology commonly used at present; This method is through detecting the MICRORNA-16 expression amount in the substrate cell; Be used for confirming that various cancer pathology develop the RNA variable quantity in early stage, the various cancerations of early warning whether take place and various cancer patients treatment after the prediction of whether recurring, shifting.Because MICRORNA-16 at normal people's high expression level, if the MICRORNA-16 expression amount reduces, explains the risk of suffering from cancer, explain that canceration takes place, or recur, shift after the cancer patient treatment, thus the diagnostic message of acquisition cancer.A test kit can many person-portions use or person-portion use.
The present invention has following beneficial effect: clinical meaning of the present invention is the more early stage variation that detects MICRORNA-16 expression amount in various canceration generations and the pathology evolution process of following the tracks of, and the various cancers of early warning take place, development trend.Diagnostic kit of the present invention and other detection and cancer markers clinically, and the medical imaging inspection has apparent difference.The present invention can detect the MICRORNA-16 unconventionality expression at rna level; Before the recurrence of occupancy carninomatosis kitchen range is not found in the medical imaging inspection; Before the cancer biochemical indicator does not produce unusually; Also do not form before the tumour, can accomplish the information acquisition of above abnormal gene expression early, predict for real early warning of clinical carninomatosis patient and treatment back transfer and relapse early.So just might implement early screening, early prevention, the early treatment of cancer, might from the source, thoroughly effect a radical cure various cancer foul diseases.
In addition, characteristics highly sensitive, high specificity that test kit provided by the invention has, simultaneously, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.
Description of drawings
Fig. 1 is a MICRORNA-16 hybridization in situ technique schema of the present invention.
Fig. 2 is that lung cancer cancer patient MICRORNA-16 expresses picture in the embodiment of the invention.
Fig. 3 is high risk population's picture in the embodiment of the invention.
Fig. 4 is that normal people MICRORNA-16 expresses picture in the embodiment of the invention.
Embodiment
Below in conjunction with embodiment, content of the present invention is described more specifically.Should be appreciated that following embodiment is used for explanation and non-limiting content of the present invention, any pro forma change or accommodation will fall into protection scope of the present invention.
Prepare the in situ hybridization test kit of present embodiment according to ordinary method, this test kit comprises that wherein: the probe mark thing of present embodiment is selected digoxin for use with hybridization probe, affinity tag, the specification sheets of MICRORNA-16 design.
The test kit hybridization solution is formed:
| Digestive system | 100 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Protection liquid | 100 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Prehybridization solution | 1300 μ L/ pipe | 2 pipe/boxes | Colourless transparent liquid |
| The justice hybridization solution | 10 μ L/ |
1 pipe/box | Colourless transparent liquid |
| The antisense hybridization solution | 10 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Confining liquid | 1000 μ L/ |
1 pipe/box | Colourless transparent liquid |
| The alkaline |
1 μ L/ |
1 pipe/box | Colourless transparent liquid |
| Developer A | 175 μ L/ |
1 pipe/box | Yellow liquid |
| Developer B | 320 μ L/ |
1 pipe/box | Colourless transparent liquid |
| The damping fluid I | The 90mL/ |
1 bottle/box | Light yellow or colourless transparent liquid |
| The damping fluid II | The 80mL/ |
1 bottle/box | Light yellow or colourless transparent liquid |
| The damping fluid III | The 20mL/ bottle | 3 bottle/boxes | Light yellow or colourless transparent liquid |
| The damping fluid IV | The 90mL/ |
1 bottle/box | Light yellow or colourless transparent liquid |
| Stationary liquid | The 90mL/ |
1 bottle/box | Colourless transparent liquid |
| The positive control sample | 6/box | ? | ? |
The reagent preparation working concentration
1). 10 * damping fluid I is diluted to 1 * damping fluid I with tri-distilled water by 1:10;
2). 20 * damping fluid II is diluted to 2 * damping fluid II with tri-distilled water by 1:10;
Be diluted to 0.2 * damping fluid II by 1:100; Be diluted to 0.1 * damping fluid II by 1:200;
3). 10 * damping fluid III is diluted to 1 * damping fluid III with tri-distilled water by 1:10;
4) .10 * damping fluid IV with tri-distilled water by 1:10 be diluted to * the damping fluid IV (get 1#, 2#, each 10mL of 3#, add water to 100mL both can).
Embodiment 2
Use the implementation process of nucleic acid hybridization in situ detection method to each group blood preparation MICRORNA-16 expression amount:
1). get two of samples to be measured;
2). in glass jar, add Digestive system (Digestive system 100 μ L add 1 * damping fluid I 99.9ml, are working concentration) 50 ml, 37 ℃ of water-bath preheating 10min put 16 slides into, handle 12 min, use 1 * damping fluid I to wash 5min again for 37 ℃;
3). (protection liquid 1ml adds 1 * damping fluid
to the protection liquid with 0.2%; 99ml is working concentration) wash 10min; Tri-distilled water is washed 5min (above process is all carried out at glass jar); Take out slide, let its seasoning;
4). slide is put into the box of preserving moisture, add prehybridization solution 25 μ L/ sheets (being added in the place of cell), covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;
5). take out slide, discard deckglass, slide is put into glass jar, the ethanol with 70%, 90%, 95% is respectively washed 2min, takes out seasoning;
6). slide is put into the box of preserving moisture, and one adds just hybridization solution 25 μ L/ sheets, and another adds antisense hybridization solution 25 μ L/ sheets, and covered is covered the box of tightly preserving moisture, and is placed on 16-24h in 42 ℃ of constant water bath box;
7). take out slide, discard deckglass, slide is put into glass jar:
In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II;
In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II;
In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;
8). wash 30s with 1 * damping fluid III, take out slide, seasoning;
9). slide is put into the box of preserving moisture, add 0.5% confining liquid (the 1ml confining liquid adds 5ml 1 * damping fluid III), 100 μ L/ sheets, cover the box of tightly preserving moisture, at room temperature act on 30min.(this step need not add deckglass);
10). take out slide, wash 30s with 1 * damping fluid III, seasoning;
11). slide is put into the box of preserving moisture; Add X-AP antibody (getting a pipe alkaline phosphatase enzyme antibody) 100 μ L/ sheets, cover the box of tightly preserving moisture and at room temperature act on 30min to wherein adding 1.8ml 1 * damping fluid III; Time can not be long, otherwise can produce false positive (this step need not add deckglass);
12). take out slide, wash 3 times, each 15min with 1 * damping fluid III;
13). wash 2min with 1 * damping fluid IV, add developer (developer A73.3 μ L, developer B157.5 μ L is added in 30mL 1 * damping fluid IV, mixing), room temperature lucifuge 16h is to more than the 18h;
14). wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.
Nucleic acid hybridization in situ detection method of the present invention is used digoxigenin labeled with goal gene; Become the RNA nucleic probe; The RNA nucleic acid to be measured of probe and human leukocytes is hybridized,, therefore under light microscopic, observe existence and the location of RNA again with the method colour developing of immunohistochemical methods; According to painted cell count, judge the expression amount of purpose RNA.
20 of lung cancer patients, 20 of high risk population (length of smoking is more than 20 years), 20 of normal control groups.Take out all people's to be checked peripheral blood 3-5 milliliter (separation white corpuscle) and do in situ hybridization.The result representes that all cancer patients MICRORNA-16 expression amounts are low, and cell dyeing is shallow; The high risk population expresses slightly and reduces, decimal dyeing; Normal control group MICRORNA-16 expression amount is high, the dyeing of cell great majority, and concrete outcome is seen Fig. 2, Fig. 3, Fig. 4.
| Lung cancer disease number | Expression amount % | High-risk number | Expression amount % | Normal number | |
| 1 | 0 | 1 | 17 | 1 | ? 82 |
| 2 | 0 | 2 | 18 | 2 | ? 72 |
| 3 | 0 | 3 | 20 | 3 | ? 77 |
| 4 | 0 | 4 | 16 | 4 | ? 80 |
| 5 | 0 | 5 | 22 | 5 | ? 72 |
| 6 | 0 | 6 | 20 | 6 | ? 90 |
| 7 | 0 | 7 | 26 | 7 | ? 85 |
| 8 | 0 | 8 | 36 | 8 | ? 67 |
| 9 | 0 | 9 | 24 | 9 | ? 80 |
| ? 10 | 1 | ? 10 | 30 | ? 10 | ? 78 |
| ? 11 | 0 | ? 11 | 32 | ? 11 | ? 72 |
| ? 12 | 0 | ? 12 | 32 | ? 12 | 76 |
| ? 13 | 0 | ? 13 | 24 | ? 13 | ? 83 |
| ? 14 | 0 | ? 14 | 27 | ? 14 | ? 78 |
| ? 15 | 0 | ? 15 | 22 | ? 15 | ? 70 |
| ? 16 | 0 | ? 16 | 28 | ? 16 | ? 82 |
| ? 17 | 0 | ? 17 | 26 | ? 17 | ? 80 |
| ? 18 | 2 | ? 18 | 22 | ? 18 | ? 90 |
| ? 19 | 0 | ? 19 | 28 | ? 19 | ? 86 |
| ? 20 | 0 | 20 | 30 | 20 | ? 76 |
。
1?gtcagcagtg?ccttagcagc?acgtaaatat?tggcgttaag?attctaaaat?tatctccagt
61?attaactgtg?ctgctgaagt?aaggttgac
Claims (10)
1. a hybridization in situ detection kit comprises hybridization probe and affinity tag, it is characterized in that, described hybridization probe is the complementary sequence of sequence shown in the sequence table SEQ ID NO.1.
2. test kit as claimed in claim 1 is characterized in that, described affinity tag is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, resorcinolphthalein, enzyme and nano material.
3. test kit as claimed in claim 1 is characterized in that this test kit also comprises hybridization solution.
4. test kit as claimed in claim 1 is characterized in that this test kit also comprises synergistic agent.
5. test kit as claimed in claim 1 is characterized in that this test kit also comprises developer.
6. microRNA-16 gene hybridization in situ detection method is characterized in that this method may further comprise the steps:
(1) can form under the condition of stablizing hybridization complex at described hybridization probe of claim 1 and target sequence, RNA to be measured in the substrate is contacted with hybridization probe, form hybridization complex; With
(2) detect said hybridization complex.
7. detection method as claimed in claim 6 is characterized in that, the described condition of stablizing hybridization complex that forms is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour.
8. detection method as claimed in claim 6 is characterized in that, described substrate is selected people's blood leucocyte sample for use.
9. detection method as claimed in claim 8 is characterized in that, described blood leucocyte sample is selected from cancer, high risk population, normal people's sample.
Develop the application in the in situ hybridization test kit 10.MICRORNA-16 detect various cancer pathology, it is characterized in that said test kit contains the described hybridization probe of claim 1 in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104260606A CN102443641A (en) | 2011-12-19 | 2011-12-19 | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104260606A CN102443641A (en) | 2011-12-19 | 2011-12-19 | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102443641A true CN102443641A (en) | 2012-05-09 |
Family
ID=46006580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104260606A Pending CN102443641A (en) | 2011-12-19 | 2011-12-19 | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102443641A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110057797A (en) * | 2019-04-24 | 2019-07-26 | 南京工业大学 | Method for detecting microRNA-155 based on mesh structure constructed by quantum dots |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101469350A (en) * | 2008-08-29 | 2009-07-01 | 芮屈生物技术（上海）有限公司 | Comprehensive detection kit for early carcinoma of prostate, detecting method and use thereof |
| CN101469351A (en) * | 2008-08-29 | 2009-07-01 | 芮屈生物技术（上海）有限公司 | Comprehensive detection kit for disgonosis, metastasis and recurrence of early prostate cancer, detecting method and use |
| CN101469348A (en) * | 2008-08-29 | 2009-07-01 | 芮屈生物技术（上海）有限公司 | In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof |
| CN101631861A (en) * | 2006-12-08 | 2010-01-20 | 奥斯瑞根公司 | As the miR-16 regulatory gene and the approach for the treatment of the target of intervening |
-
2011
- 2011-12-19 CN CN2011104260606A patent/CN102443641A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101631861A (en) * | 2006-12-08 | 2010-01-20 | 奥斯瑞根公司 | As the miR-16 regulatory gene and the approach for the treatment of the target of intervening |
| CN101469350A (en) * | 2008-08-29 | 2009-07-01 | 芮屈生物技术（上海）有限公司 | Comprehensive detection kit for early carcinoma of prostate, detecting method and use thereof |
| CN101469351A (en) * | 2008-08-29 | 2009-07-01 | 芮屈生物技术（上海）有限公司 | Comprehensive detection kit for disgonosis, metastasis and recurrence of early prostate cancer, detecting method and use |
| CN101469348A (en) * | 2008-08-29 | 2009-07-01 | 芮屈生物技术（上海）有限公司 | In situ hybridization detection kit for early carcinoma of prostate, detecting method and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 李明: "10种miRNAs在前列腺癌组织中的表达及意义", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, 15 April 2010 (2010-04-15), pages 072 - 196 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110057797A (en) * | 2019-04-24 | 2019-07-26 | 南京工业大学 | Method for detecting microRNA-155 based on mesh structure constructed by quantum dots |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102559881A (en) | Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for neoplasia early stage of intracranial glioma, and detection method and application | |
| CN102443641A (en) | Various early-stage cancer pathology evolution MICRORNA-16 level in situ hybridization detection kit, detection method thereof and application thereof | |
| CN102443647A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-145 level at pathologic evolution early stages of various colon cancers as well as microRNA-145 in-situ hybridization detection method and application of microRNA-145 to preparation of in-situ hybridization detection kit for colon cancers | |
| CN102443643A (en) | Kit for assaying MICRORNA-34 level in early stage of pathologic evolution of various cancers through in situ hybridization and assay method and application | |
| CN102443642A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-92A level at pathologic evolution early stage of colon cancer as well as microRNA-92A in-situ hybridization detection method and application of microRNA-92a to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102443644A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-29A level at pathologic evolution early stage of colon cancer as well as microRNA-29A in-situ hybridization detection method and application of microRNA-29a to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102586419A (en) | MRNA level in-situ hybridization detection kit for beta-catenin of liver cancer prophase as well as detection method and application of mRNA level in-situ hybridization detection kit | |
| CN102533976A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-21 at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN102533990B (en) | In situ hybridization detection kit for mRNA level at precancerous stage of breast cancer, detection method and application thereof | |
| CN102559887A (en) | Messenger ribonucleic acid (mRNA) level in-situ hybridization detection kit for JAGGED1 in early stage of pathological change of breast cancer bone metastasis, and detection method and application | |
| CN102559884A (en) | LET-7micro ribose nucleic acid (MIRNA) level in-situ hybridization detection kit for pathologic evolution early stage of various cancer, and detection method and application | |
| CN102533986A (en) | MicroRNA-15a-level in-situ hybridization detection kit for prophase of cancer pathologic evolution, detection method and application | |
| CN102559876A (en) | Level in situ hybridization detection kit for detecting MICRORNA-16-1 in earlier period of pathological changes of cancers as well as detection method and application | |
| CN102533987A (en) | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA-143 in earlier stage of cancer pathologic evolution | |
| CN102443650A (en) | In-situ hybridization detection kit for MICRORNA (MICRO Ribonucleic Acid)-233 level at pathologic evolution early stage of colon cancer as well as microRNA-233 in-situ hybridization detection method and application of microRNA-233 to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102443646A (en) | In situ hybridization detection kit for MICRORNA-223 level of early-stage lung cancer pathology evolution, detection method thereof and application thereof | |
| CN102443645A (en) | In-situ hybridization detection kit and detection method for MICRORNA (MICRO Ribonucleic Acid)-25 level at pathologic evolution early stage of colon cancer as well as application of microRNA-25 to preparation of in-situ hybridization detection kit for colon cancer | |
| CN102443648A (en) | Kit for detecting horizontal in situ hybridization of MICRORNA-182 in early stage of pathological evolution of various cancers, detection method and application | |
| CN102443649A (en) | Kit for detecting horizontal in situ hybridization of MICRORNA-141 at early stage of pathological evolution of various cancers, detection method and application | |
| CN102628078A (en) | MicroRNA-155 level in-situ hybridization detection kit for early stage of various cancer lesions, detection method and application | |
| CN102533984A (en) | Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA17-3P in earlier stage of cancer pathologic evolution | |
| CN102533980A (en) | Kit and method for detecting horizontal in situ hybridization of MICRORNA-10B at the early pathological evolution stage of a variety of cancers and application thereof | |
| CN102453768A (en) | In-situ hybridization detection kit for mRNA level in early stage of brain glioma neoplasia, detection method and application | |
| CN102605060A (en) | In-situ hybridization assay kit for premalignant lung cancer 14-3-3thta level as well as assay method and application | |
| CN102605056A (en) | In-situ hybridization assay kit for mRNA level of premalignant pancreatic cancer ATDC (telangiectasia group D associated protein) gene as well as assay method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120509 |